CA2315693C - Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases - Google Patents

Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases Download PDF

Info

Publication number
CA2315693C
CA2315693C CA2315693A CA2315693A CA2315693C CA 2315693 C CA2315693 C CA 2315693C CA 2315693 A CA2315693 A CA 2315693A CA 2315693 A CA2315693 A CA 2315693A CA 2315693 C CA2315693 C CA 2315693C
Authority
CA
Canada
Prior art keywords
alkyl
substituted
aryl
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2315693A
Other languages
English (en)
French (fr)
Other versions
CA2315693A1 (en
Inventor
Walter R. Bishop
Joseph J. Catino
Ronald J. Doll
Ashit Ganguly
Viyyoor M. Girijavallabhan
Paul Kirschmeier
Ming Liu
Loretta L. Nielsen
David L. Cutler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27385940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2315693(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of CA2315693A1 publication Critical patent/CA2315693A1/en
Application granted granted Critical
Publication of CA2315693C publication Critical patent/CA2315693C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2315693A 1997-12-22 1998-12-21 Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases Expired - Fee Related CA2315693C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US99602797A 1997-12-22 1997-12-22
US08/996,027 1997-12-22
US14352998A 1998-08-28 1998-08-28
US09/143,529 1998-08-28
US18196998A 1998-10-29 1998-10-29
US09/181,969 1998-10-29
PCT/US1998/026224 WO1999032114A1 (en) 1997-12-22 1998-12-21 Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases

Publications (2)

Publication Number Publication Date
CA2315693A1 CA2315693A1 (en) 1999-07-01
CA2315693C true CA2315693C (en) 2010-11-30

Family

ID=27385940

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2315693A Expired - Fee Related CA2315693C (en) 1997-12-22 1998-12-21 Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases

Country Status (25)

Country Link
EP (1) EP1041985B1 (enExample)
JP (1) JP4502503B2 (enExample)
KR (1) KR100700907B1 (enExample)
CN (1) CN1129431C (enExample)
AR (1) AR017440A1 (enExample)
AT (1) ATE317697T1 (enExample)
AU (1) AU756762B2 (enExample)
BR (1) BR9814419A (enExample)
CA (1) CA2315693C (enExample)
CL (1) CL2007001889A1 (enExample)
CO (1) CO5080764A1 (enExample)
CZ (1) CZ298511B6 (enExample)
DE (1) DE69833509T2 (enExample)
DK (1) DK1041985T3 (enExample)
ES (1) ES2255196T3 (enExample)
HU (1) HUP0102473A3 (enExample)
IL (1) IL136462A0 (enExample)
MY (1) MY137303A (enExample)
NO (1) NO326832B1 (enExample)
NZ (1) NZ504928A (enExample)
PE (1) PE20000042A1 (enExample)
PT (1) PT1041985E (enExample)
SK (1) SK285584B6 (enExample)
TW (1) TW581763B (enExample)
WO (1) WO1999032114A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2787327B1 (fr) * 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase
DE60016625T2 (de) * 1999-11-09 2005-12-22 Societe De Conseils De Recherches Et D'applications Scientifiques(S.C.R.A.S.) Zusammensetzung enthaltend einen inhibitor der signaltransduktion von heterotrimerischen g-proteinen in kombination mit einem anderen anti-krebs-mittel zu einer therapeutischen verwendung in der krebsbehandlung
AU2292801A (en) * 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
US20030186925A1 (en) * 2000-02-29 2003-10-02 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
EP1261348A2 (en) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
WO2001064197A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
WO2001064226A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with platinum compounds
WO2001064196A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
EP1267871A2 (en) * 2000-02-29 2003-01-02 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US6645966B2 (en) * 2001-01-22 2003-11-11 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
JP4969016B2 (ja) * 2001-02-15 2012-07-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗エストロゲン剤とファルネシルプロテイントランスフェラーゼ阻害剤の組み合わせ物
HUP0402401A2 (hu) * 2001-11-30 2005-03-29 Schering Corp. Rák kezelésére szolgáló eljárások egy FPT inhibitor és daganatellenes szerek felhasználásával
EP1453513A1 (en) * 2001-12-03 2004-09-08 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
CN105198758A (zh) * 2015-09-22 2015-12-30 湖南大学 一种高纯度(z)-他莫昔酚的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
AU665341B2 (en) * 1990-12-18 1996-01-04 Wellcome Foundation Limited, The Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
JP2767176B2 (ja) * 1992-12-15 1998-06-18 大塚製薬株式会社 抗癌剤
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
DE69635114T2 (de) * 1995-08-09 2006-03-02 Banyu Pharmaceutical Co., Ltd. Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids
TW350844B (en) * 1995-12-22 1999-01-21 Schering Corp Tricyclic amides useful to inhibition of G-protein function and for treatment of proliferative diseases
EP0932399B1 (en) * 1996-03-12 2006-01-04 PG-TXL Company, L.P. Water soluble paclitaxel prodrugs
JP2000507584A (ja) * 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質転移酵素の阻害剤
US20020034725A1 (en) * 1996-04-15 2002-03-21 W. Gillies Mckenna Sensitization of cells to radiation and and chemotherapy
CA2251955A1 (en) * 1996-04-18 1997-10-23 Nancy E. Kohl A method of treating cancer
JP2000508335A (ja) * 1996-05-30 2000-07-04 メルク エンド カンパニー インコーポレーテッド 癌の治療方法
US6337992B1 (en) * 1997-01-29 2002-01-08 Philips Medical Systems Technologies Ltd. Predictive bolus tracking
CA2282683A1 (en) * 1997-02-18 1998-08-20 Canji, Inc. Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms

Also Published As

Publication number Publication date
CL2007001889A1 (es) 2008-01-11
EP1041985A1 (en) 2000-10-11
DE69833509T2 (de) 2006-10-26
CN1129431C (zh) 2003-12-03
AU756762B2 (en) 2003-01-23
CN1284875A (zh) 2001-02-21
PT1041985E (pt) 2006-07-31
SK8982000A3 (en) 2001-04-09
NO326832B1 (no) 2009-02-23
JP2001526224A (ja) 2001-12-18
AR017440A1 (es) 2001-09-05
NZ504928A (en) 2004-12-24
HUP0102473A3 (en) 2003-07-28
BR9814419A (pt) 2000-10-10
CA2315693A1 (en) 1999-07-01
CZ20002236A3 (cs) 2001-04-11
ATE317697T1 (de) 2006-03-15
WO1999032114A1 (en) 1999-07-01
IL136462A0 (en) 2001-06-14
KR100700907B1 (ko) 2007-03-29
ES2255196T3 (es) 2006-06-16
CZ298511B6 (cs) 2007-10-24
TW581763B (en) 2004-04-01
HUP0102473A2 (hu) 2002-01-28
CO5080764A1 (es) 2001-09-25
NO20003229L (no) 2000-08-22
DE69833509D1 (de) 2006-04-20
AU1907299A (en) 1999-07-12
EP1041985B1 (en) 2006-02-15
PE20000042A1 (es) 2000-02-17
DK1041985T3 (da) 2006-06-19
KR20010033452A (ko) 2001-04-25
MY137303A (en) 2009-01-30
JP4502503B2 (ja) 2010-07-14
NO20003229D0 (no) 2000-06-21
SK285584B6 (sk) 2007-04-05

Similar Documents

Publication Publication Date Title
US6333333B1 (en) Methods for treating proliferative diseases
CA2315693C (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
RU2264217C2 (ru) Синергические способы и композиции для лечения рака
AU2001247683A1 (en) Synergistic methods and compositions for treating cancer
CA2364675A1 (en) Methods of inducing cancer cell death and tumor regression
IL157443A (en) Pharmacological preparations for the treatment of cancer that contain an analogue of apothelone and a chemotherapeutic agent
JP7273791B2 (ja) 腫瘍成長を阻害するＣＨＫ１（ＳＲＡ７３７）／ＰＡＲＰｉ組み合わせ方法
CA2424797C (en) Methods of inducing cancer cell death and tumor regression
AU2002211862A1 (en) Methods of inducing cancer cell death and tumor regression
US20030114504A1 (en) Compositions and methods for the treatment of cancer
MXPA00006257A (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
Schimmer et al. Discovery and evaluation of anticancer drugs
Schimmer et al. Basic Science of Oncology,(McGraw-Hill International Editions)

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20141222